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Abstract
Background: Onchocerciasis or “river blindness” is a chronic parasitic disease caused by the filarial worm
Onchocerca volvulus, transmitted through infected blackflies (Simulium spp.). Bioko Island (Equatorial Guinea) used to
show a high endemicity for onchocerciasis. During the last years, the disease control programmes using different
larvicides and ivermectin administration have considerably reduced the prevalence and intensity of infection. Based
on this new epidemiological scenario, in the present work we aimed to assess the impact of the strategies applied
against onchocerciasis in Bioko Island by an evaluation of IgG4 antibodies specific for recombinant Ov-16 in ELISA.
Methods: A cross-sectional study was conducted in Bioko Island from mid-January to mid-February, 2014. Twenty
communities were randomly selected from rural and urban settings. A total of 140 households were chosen. In
every selected household, all individuals aged 5 years and above were recruited; 544 study participants agreed to
be part of this work. No previous data on onchocerciasis seroprevalence in the selected communities were
available. Blood samples were collected and used in an “ELISA in-house” prepared with recombinant Ov-16,
expressed and further purified. IgG4 antibodies specific for recombinant Ov-16 were evaluated by ELISA in all of the
participants.
Results: Based on the Ov-16 ELISA, the onchocerciasis seroprevalence was 7.9 %, mainly concentrated in rural
settings; samples from community Catedral Ela Nguema (# 16) were missed during the field work. Among the rural
setups, communities Inasa Maule (# 7), Ruiché (# 20) and Barrios Adyacentes Riaba (# 14), had the highest
seropositivity percentages (29.2, 26.9 and 23.8 %, respectively). With respect to the urban settings, we did not find
any positive case in communities Manzana Casa Bola (# 3), Colas Sesgas (# 6), Getesa (# 8), Moka Bioko (# 9),
Impecsa (# 10), Baney Zona Baja (# 12) and Santo Tomás de Aquino (# 1). No onchocerciasis seropositive samples
were found in 10-year-old individuals or younger. The IgG4 positive titles increased in older participants.
Conclusions: A significant decline in onchocerciasis prevalence was observed in Bioko Island after years of disease-vector
control and CDTI strategy. The seroprevalence increased with age, mainly in rural settings that could be due to previous
exposure of population to the filarial parasite, eliminated by the control programmes introduced against onchocerciasis. A
new Ov-16 serological evaluation with a larger sample size of children below 10 years of age is required to demonstrate
the interruption of transmission of O. volvulus in the human population of Bioko Island (Equatorial Guinea) according to
the WHO criteria.
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Background
Onchocerciasis or “river blindness” is a chronic parasitic
disease caused by the filarial worm Onchocerca volvulus.
It is transmitted through the repeated bites of infected
blackflies (Simulium spp.) from human to human. In the
human body, the larvae form nodules in the subcutane-
ous tissue, where they mature to adult worms. After
mating, the female adult worm release microfilariae
(MF) that move through the body. When MF die they
cause a variety of pathological conditions, affecting prin-
cipally eyes and skin [1].
In 1974, the onchocerciasis control programme (OCP)
was launched in the African continent, with the aim of
eliminating the vector blackfly by regular aerial larvicid-
ing. This strategy was encouraged by the decision taken
by Merck in 1987 to make ivermectin (Mectizan) avail-
able free of charge through the Mectizan Donation
Programme (MDP) [2]. Later on, in 1995, the African
Programme for Onchocerciais Control (APOC) begun
annual administration of the community-directed treat-
ment with ivermectin (CDTI) [3, 4]. APOC based the
drug administration on the previous assessment of the
local disease endemicity by rapid epidemiological map-
ping of onchocerciasis (REMO) [5]. All these interven-
tions have demonstrated efficacy in controlling
onchocerciasis as a public health problem in Africa [6].
Bioko Island, located in Equatorial Guinea, used to
show a high endemicity for onchocerciasis [7, 8]. The
introduction of the disease control programmes, men-
tioned above, allowed the reduction in the prevalence
and intensity of infection [9], and the presumptive elim-
ination of the onchocerciasis vector, the Bioko form of
Simulium yahense [10]. The CDTI has been continued
until now. At this stage, surveillance and evaluation ac-
tivities are especially necessary to verify that the parasite
transmission has been interrupted [11]. Onchocerciasis
detection has been traditionally carried out by nodule
palpation and microscopic examination of MF in skin
snips, although nodule palpation has poor diagnostic
precision and morphological MF identification requires
substantial expertise, is time-consuming and shows poor
sensitivity [12]. In locations where onchocerciasis preva-
lence has dropped down thanks to CDTI, and disease
elimination needs to be evaluated, new survey and diag-
nostic tools are required. Therefore, innovative strategies
for onchocerciasis accurate diagnosis, immunological
and DNA-molecular approaches, have been developed
during the last decades [13–15].
Within immunodiagnosis options, the evaluation of
IgG4 responses to the Ov-16 antigen, by ELISA and/or
rapid-format card test, has emerged as an alternative
tool to determine the impact of the disease elimination
progress [16, 17]. Onchocerca volvulus-Ov-16 antigen be-
longs to the phosphatidylethanolamine-binding protein
family (A.N.: P31729 [18, 19]), and expressed as a recom-
binant antigen allowed the early and specific detection of
new Onchocerca infections in children, with good sensitiv-
ity [17]. WHO has been using the Ov-16/IgG4 system to
verify the interruption of transmission of human oncho-
cerciasis, besides ophthalmological and/or entomo-
logical assessments, since 2001 [20]. This serological
approach has been employed, among others, to certify
the transmission suppression of onchocerciasis in the
Americas [21–23] and in some African endemic
regions [4, 24, 25], and again it has been recently
recommended by WHO in the last onchocerciasis
guidelines [26].
The present work represents a preliminary study,
which aimed to assess the impact of CDTI strategy on
onchocerciasis control in Bioko Island by the evaluation




The study took place in Bioko Island from mid-January
to mid-February, 2014. The Island is a part of the
Republic of Equatorial Guinea, which also includes Rio
Muni on the mainland and the island of Annobon. Bioko
Island comprises two zones: Bioko Norte (Malabo,
Baney and Rebola districts) and Bioko Sur (Luba and
Riaba districts). It is located in the Bay of Guinea in
Central Africa, about 40 km southwest of the Cameroon
coast. The surface area of Bioko Island is of approxi-
mately 2017 km2 and it is about 72 km in length. Most
of the 260,000 inhabitants live in the capital, Malabo.
The island has a humid tropical climate. Mean daily
maximum and minimum temperatures range between
29–32 °C and 19–22 °C, respectively. The rainfall is
highly seasonal, with a dry season which lasts from
December to April; many of the rivers and streams dry
up soon after the end of the rainy season. Before the
elimination of the vector blackfly, the levels of vector
biting were lowest during January to April coinciding
with the dry season reduction in suitable breeding
sites [27]. Currently, seasonality and rainfall are not
expected to influence the transmission of O. volvulus,
as there is no evidence of vector re-emergence in the
island since 2005.
Study design, sample size and sampling technique
A cross-sectional study was conducted. Sampling was
carried out by multistage cluster survey. The sample size
was computed using Epi-Info version 3.4.1 free software
considering the following parameters: hypothesized
prevalence of 10 % and a standard error of 2 %. We
assumed a design effect of 2, corresponding to the com-
plex design. The initial sample size was 450. It was
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increased (+20 %) in prevision of missing data. The
equation used is included below: n = DEFF p (1-p)/e^2,
where DEFF is the design effect, e is the desired stand-
ard error and p is the prevalence.
First, 20 communities were randomly selected with
probability proportional to size (Fig. 1). Secondly, sam-
pling units were randomly selected households from an
updated census from each community, provided by the
head of the village (in rural areas) or neighbourhood (in
urban zones). In every selected household, all individuals
over 5 years of age who had permanently lived in Bioko
Island during the last 5 years were recruited. People who
were born outside Equatorial Guinea were excluded.
Data collection
A closed-ended structured questionnaire was administered
to every study participant by trained medical personnel.
The questionnaire comprised socio-demographic and clin-
ical information and was pre-tested on close areas not
included in this study for clarity and cultural acceptability.
Each interview was made by house-to-house visit. If the
study participant was less than 15 years of age, the
questionnaire was answered by a parent or guardian. Those
children under 5 years of age, no Equatoguinean national-
ity, and/or who had changed residence in the last 5 years
were excluded.
The coordinates (longitude and latitude) of every
selected household were also recorded on-site using
Dakota™10 Garmin single handheld GPS receivers.
Skin-snips
Three skin snips specimens were collected from every
participant (two from right iliac crest, one from left iliac
crest). No special collection time was considered as the
microfilariae of O. volvulus are non-periodic. Two sam-
ples were immersed in normal saline solution to prevent
the preparation from drying out and sent to the local
hospital laboratory to be read under a microscope
(magnification of 100×) after 24 h. Results were
expressed for each individual as ‘positive’ or ‘negative’.
Laboratory results were recorded on the original (field)
registration form.
Blood samples
Blood drops were taken from peripheral blood samples
that were collected from each individual [28] and placed
on a label circle of Whatman No. 2 filter paper (Milipore).
Filter paper blood samples were dried, individually
wrapped in plastic bags with a silica desiccant and stored
in coolers at 4 °C until they could be transferred to a
refrigerator, where they were stored until further analysis.
Production of Ov-16 recombinant antigen
The Ov-16 nucleotide sequence [18], without the signal
peptide, was amplified by PCR from a recombinant
pMAL-Ov-16 plasmid, kindly donated by Professor JE
Bradley, School of Life Sciences and University of
Nottingham, UK. A poly-His tail was added to the
carboxy-terminus of the amplified Ov-16 sequence,
Fig. 1 Distribution of the randomly selected community clusters, Bioko Island, Equatorial Guinea: #1, Santo Tomás de Aquino; #2, Baney Zona
Media B1; #3, Manzana Casa Bola; #4, Zona Alta A1 Baney; #5, Alcalde 1 Malabo; #6, Colas Sesgas; #7, Inasa Maule; #8, Getesa; #9, Moka Bioko; #10,
Impecsa; #11, Bilelipa; #12, Baney Zona Baja; #13, Santa Maria 4B Malabo; #14, Barrios Adyacentes Riaba; #15, Sampaka 1 Malabo; #17, Zona “D” C/
N° 1–25 Malabo; #18, Cachirulo; #19, Santa María 4A; #20, Ruiché
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which was then subcloned into pGEX-6P-1 plasmid (GE
Healthcare, Little Chalfont, UK), a glutathione S-
transferase fusion vector. The GST-Ov-16 recombinant
protein was purified by Glutathione Sepharose 4B affin-
ity chromatography (GE Healthcare) according to the
manufacturer’s recommendations. Later, separation of
the recombinant protein from the glutathione S-
transferase moiety was accomplished by site-specific
proteolysis using PreScissionTM Protease reaction (GE
Healthcare). After dialyzing against PBS, the Ov-16-
His recombinant protein was repurified by Ni2+ Seph-
arose 4B affinity chromatography (GE Healthcare) ac-
cording to the manufacturer’s recommendations.
Finally, the Ov-16-His was again dialyzed against PBS
and quantified with Pierce™ BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL, USA).
Serological assessment
In-house ELISA test
In the laboratory, serum samples were eluted from
Whatman filter paper as follows. Four 3 mm-punches of
blood saturated filter paper were placed in 200 μl of
dilution buffer (phosphate-buffered saline (PBS)-Tween 20
0.05 %-skim milk 3 %) and eluted overnight at 4 °C, ac-
cording to Lindblade et al. [29] with small modifications.
The serum elution was run in duplicate in a standard
enzyme-linked immunosorbent assay (ELISA) to detect
IgG4 antibodies against the Ov-16 recombinant antigen
essentially as previously described [25]. Briefly, 96-well
polystyrene plates (Nunc MaxiSorp® flat-bottom 96 well
plate) were sensitized with the purified Ov-16 recombinant
protein (0.5 μg/ml; 100 μl/well) in carbonate buffer pH 9.6,
overnight at 4 °C. Later, the plates were washed three times
with phosphate PBS, pH 7.4 plus 0.05 % Tween 20 (PBST,
washing buffer) and blocked in dilution buffer (PBST plus
0.3 % skim milk) for 1 h at 37 °C. After blocking, plates
were washed 3 times as described above. The diluted serum
samples (100 μl) were added in duplicate to the corre-
sponding wells; eluted positive and negative controls,
equally processed and diluted, were also introduced. After
1 h of incubation at 37 °C, the plates were PBST-washed 5
times and bound antibodies were detected by exposure to
horseradish peroxidase conjugated mouse anti-human
IgG4 (Southern Biotech, Birmingham, AL, USA), 1/4000 in
PBST; the plates were incubated and washed as described
above. The substrate buffer was prepared with an ABTS
tablet (2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic
acid) diammonium salt; Sigma-Aldrich, A9941, Saint Louis,
MO, USA) plus 20 ml of phosphate-citrate buffer with
sodium perborate (Sigma-Aldrich P4922); 100 μl of sub-
strate buffer was added to each well and then the plate was
incubated at 37 °C in darkness. The plates were read at
405 nm with a 620 nm reference filter when the 1/8 posi-
tive control dilution was around 0.5 OD (see below).
We used a standard curve on each plate to identify
positive samples and permit comparisons between plates
and over days, as previously described [25, 29]. The
standard curve was prepared using a positive onchocer-
ciasis sample, obtained from an onchocerciasis patient
confirmed by both clinical manifestations and parasito-
logical diagnosis; the standard curve dilutions (1/8; 1/16;
1/32; 1/64; 1/128) were prepared through elution of the
blood sample placed on a Whatman filter paper. Each of
these dilutions was assigned the arbitrary units shown in
Table 1. The cut-off was determined after analyzing 83
negative samples from sub-Saharan (n = 33) /Spanish/
Latin American individuals and 5 positive samples
(parasitologically and clinically confirmed as O. volvulus-
positive individuals). The cut-off was set at 40 arbitrary
units corresponding to the 1/64 dilution by identifying
the value that optimized both sensitivity and specificity.
Commercial test
Positive onchocerciasis samples by ELISA-Ov-16/IgG4
were re-tested in a rapid format for the detection of
IgG4 antibodies against Ov-16 recombinant antigen (SD
Onchocerciasis IgG4-Bioline, Standard Diagnostics, Inc.,
Gyeonggi, South Korea); the procedure shows a sensitiv-
ity of 81.1 % and a specificity of 99.0 % according to the
manufacturer. The immunochromatographic tests were
developed following the manufacturer’s recommenda-
tions, using 10 μl blood samples. We considered a
sample as positive when it was possible to see a red line
on the test line even when the line was very weak.
Data analysis
The collected data were double entered into a data entry
file using EpiData software, V.3.1. Frequencies, means
and standard deviations (SD) were computed to
summarize the data. Antibody prevalence was defined as
the proportion of positive results among subjects who
had definite results for the Ov-16 ELISA. Bivariate ana-
lyses by age group were performed with χ2 test for
Table 1 Standard curve dilutions on each Ov-16-IgG4 ELISA
plate. The mean and standard deviation obtained for each
dilution and the arbitrary units assigned to each dilution are
shown. The plates were read when the 1/8 dilution reached a
0.5 OD value. The 1/64 dilution was determined as the cut-off,
hence samples with OD-values above this value were considered
positive
Standard curve dilutions Target mean (OD) Standard deviation Units
1/8 0.512 0.058 320
1/16 0.243 0.032 160
1/32 0.119 0.020 80
1/64 0.061 0.010 40
1/128 0.032 0.005 20
The cut-off dilution and the corresponding OD value are marked in bold
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categorical data. Where a cell value was below 5, Fisher’s
exact test for two-way tables was applied. The criterion
for significance was set at P < 0.05 based on a two-sided
test. All statistical analyses were performed using SPSS
v.22 (SPSS Inc., Chicago, Illinois, USA).
Results and discussion
A total of 140 houses and 544 study participants
agreed to be part of this study. None of the 544 skin
snip assessments for MF detection was found positive
(data not shown). Blood samples on Whatman paper
were collected and analyzed from 531 participants, as
the samples from community # 16 were missed dur-
ing the field work.
Based on the Ov-16 ELISA, the data obtained in the
study of the 19 communities showed that the onchocer-
ciasis seroprevalence was 7.9 %, mainly concentrated in
rural settings (Table 2). To confirm this result, the
positive samples were checked by a commercial test that
yielded similar data (40 were positive, 1 was undeter-
mined and 1 negative).
Table 3 shows the distribution of the onchocerciasis-
seropositive individuals in the different surveyed
communities. As indicated above, rural communities
exhibited the highest number of seropositive individuals
for onchocerciasis, with significant differences in rela-
tion to the urban ones. Among the rural setups, com-
munities # 7, # 20 and # 14, had the highest
seropositivity percentage (29.2, 26.9 and 23.8 %,
respectively). The higher prevalence detected in rural
communities emphasizes the problem of control strat-
egies implementation in this kind of setting due to
difficulties in access, cultural barriers and preference
for traditional methods which has already been
observed before [30]. With respect to the urban
settings, we did not find any positive case in commu-
nities # 3, # 6, # 8, # 9, # 10, # 12 and # 17, although
communities # 2 and # 18 showed 15.2 and 14.3 % of
seropositivity, respectively.
The seroprevalence by age group was also assessed.
No positive samples were found in 10 year-old individ-
uals or younger, while participants older than 50 years
were the ones with the highest prevalence (χ2 = 33.762,
df = 4, P < 0.001), being 19 % onchocerciasis positive by
Ov-16-ELISA (Fig. 2). The percentage of individuals with
an undetermined serology increased with age (Fig. 2). A
sample was considered undetermined when its absorb-
ance was on the pre-defined cut-off, 40 arbitrary units
(Table 1). These undetermined results could corres-
pond to individuals previously in contact with the
filaria, which after effective treatment with ivermectin,
were losing antibodies to Ov-16 to finally become
seronegative.
In this paper we evaluated serologically (Ov-16-ELISA)
the impact of control programmes on onchocerciasis
carried out in Bioko Island, Equatorial Guinea. We
observed a significant decrease in the disease prevalence
after years of ivermectin administration; the decline
(IgG4 antibody title) was less pronounced in rural com-
munities and individuals aged 10 years and above. Previ-
ously published data by Mas et al. [9] showed a
reduction in the prevalence and intensity in O. volvulus
after 8 years of CDTI on Bioko Island; the authors
selected rural communities, examined more than 1000
individuals by MF counts in skin-snips, and found out
that the disease prevalence had decreased from 74.5 to
38.4 % in the period 1989–1998. The ivermectin distri-
bution continued over time thanks to APOC, reaching
coverages between 50 and 75 % in most endemic areas
[31]. In parallel, the demonstration of the elimination of
the Bioko form S. yahense (larviciding with temephos,
2001–2005) [10] promoted a new epidemiological
scenario with a sharp decline in parasite load. In such
epidemiological situation, more sensitive and specific
diagnosis tools, as genomic procedures (PCR) and/or
recombinant antigens-serology would be needed in
order to evaluate the potential interruption of filarial
transmission in Bioko Island. The Ov-16 serology with
IgG4-system [18, 19, 29] has been a major advance in
the fight against onchocerciasis. It has been widely used
for certification of the elimination of the disease in the
Americas [32] and in some African regions [4, 24, 25].
The Ov-16 antigen exhibits an excellent performance for
onchocerciasis diagnosis, although some cross-reactions
with Mansonella ozzardi have been reported [19, 33].
Mansonella ozzardi is not present in Africa, so the
handicap previously referred is not relevant to the
present study. No such cross-reactivity with the other
Mansonella spp. has been reported [16, 19]. Neverthe-
less, it an in-depth analysis of this aspect would be desir-
able considering that Mansonella perstans and
Mansonella streptocerca are co-endemic with O. volvulus
and highly prevalent in Africa [34]. With respect to sen-
sitivity, Ov-16-IgG4 assay works as an early and specific
marker for O. volvulus infection [19]. Interestingly, in
the present work only positive IgG4 levels were detected
in approximately 7.9 % of the tested population, in indi-
viduals aged 11 years and above and mainly settled in
Table 2 Number (percent) of positive samples in Ov16/IgG4-
ELISA regarding community type. Statistically significant
differences were found between rural and urban settings:
Chi-square test: χ2 = 13.25, df = 2, P < 0.001
Setting Positive samples (n) Percent positive samples 95 % CI
Rural (n = 219) 29 13.2 9.4–18.4
Urban (n= 312) 14 4.5 2.7–7.4
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Fig. 2 Onchocerciasis seropositivity for age groups. Y axis, number of samples. Statistically significant differences were found between percentage
of positivity in age groups by Chi-square test (χ2 = 33.762, df = 4, P < 0.001). Note: There is a positive sample that was not included because the
person's age was unknown
Table 3 OV16-IgG4 seropositivity distribution in the surveyed communities. Total number of individuals checked in each
community, the number of positive, negative and dubious samples in each community (n) and the percent (%) of positivity,




Total NEG UND POS
n % n % n %
1 Santo Tomás de Aquino Urban 12 11 91.7 0 0 1 8.3
2 Baney Zona Media B1 Rural 33 27 81.8 1 3.0 5 15.2
3 Manzana Casa Bola Urban 26 26 92.9 0 0 0 0
4 Zona Alta A1 Baney Rural 35 31 86.1 1 2.9 3 8.6
5 Alcalde 1 Malabo Urban 27 24 85.7 0 0 3 11.1
6 Colas Sesgas Urban 31 31 100.0 0 0 0 0
7 Inasa Maule Rural 24 16 66.7 1 4.2 7 29.2
8 Getesa Urban 30 29 90.6 1 3.3 0 0
9 Moka Bioko Rural 21 19 90.5 2 9.5 0 0
10 Impecsa Urban 30 27 90.0 3 10.0 0 0
11 Bilelipa Rural 25 21 80.8 2 8.0 2 8.0
12 Baney Zona Baja Rural 34 32 94.1 2 5.9 0 0
13 Santa Maria 4B Malabo Urban 39 37 92.5 1 2.6 1 2.6
14 Barrios Adyacentes Riaba Rural 21 16 72.2 0 0 5 23.8
15 Sampaka 1 Malabo Urban 38 33 86.8 1 2.6 4 10.5
17 Zona “D” C/N° 1–25 Malabo Urban 17 17 94.4 0 0 0 0
18 Cachirulo Urban 21 18 85.7 0 0 3 14.3
19 Santa María 4A Urban 41 39 86.7 0 0 2 4.9
20 Ruiché Rural 26 19 73.1 0 0 7 26.9
Abbreviations: ID identification number, NEG negative results, POS positive results, UND undetermined results
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rural areas. The prevalence determined was significantly
lower than that reported by Mas et al. [9]. Nevertheless,
it should be taken into account that Mas and co-workers
used MF count that is much less sensitive than immuno-
diagnosis. Moreover, ivermectin administration has been
continued over the last years.
In addition, it should be emphasized that according
to the age, the younger population (5–10 year-old)
did not present positive serology, meaning that no
IgG4 antibodies were detected. This result is ex-
tremely important, in view of the fact that the ab-
sence of specific IgG4 antibodies highlights no
parasite infection in children of Bioko Island, and
therefore points to the possible interruption of para-
site transmission in the region. Regarding the sero-
logically positive individuals, it should be considered
that according to Weil et al. [16], the seropositivity
obtained in treated patients could be due to a pro-
gressive decline of IgG4 antibodies to Ov-16 over a
period of years after apparent onchocerciasis curing.
In this sense, the study carried out by Traoré et al.
[10] showed the presumptive elimination of the vector
of O. volvulus in the island since 2005. These results
support the interruption of parasite transmission and
human infection. Nevertheless, new entomological as-
sessments to verify S. yahense elimination are desir-
able, including the study of other potential vectors
which can become infected by the parasite and thus
replace the old vector [35].
Our study has some limitations. First, the possibility
of cross-reaction of Ov-16 ELISA test with some of
Mansonella spp., highly prevalent in Africa, should be
assessed in the future. Secondly, like other serological
tests, the Ov-16 ELISA cannot differentiate recent
from historical exposure. Moreover, it is currently not
known how long the IgG4 antibody response to the
Ov-16 antigen persists. Therefore, a larger number of
samples would be necessary in order to define a more
accurate seroprevalence in Bioko Island. Also, it
would be required to increase the number of samples
from children in each community to assess the pos-
sible interruption of transmission, since this will allow
us to detect possible hot spots.
Conclusions
In the present work, a decline in onchocerciasis preva-
lence in humans was determined in Bioko Island after
years of vector control measures and CDTI strategy.
Nevertheless, the sample population was not large
enough and only children above 5 years of age were
tested. In the age group 5–10 year-old, none individual
had IgG4 antibodies against recombinant Ov-16. More-
over, the Ov-16 seroprevalence increased with age,
especially in rural settings, and no O. volvulus microfil-
ariae were observed in skin-snips.
Further serological studies with larger human sam-
ples are needed, especially in children younger than
10 years, as recommended by recent updated WHO
criteria (2016). Besides Ov-16 serology, the verifica-
tion of S. yahense elimination in Bioko Island and the
absence of parasite DNA in both human skin-snips
and other potential simulid vectors are recommended
to confirm the interruption of onchocerciasis trans-
mission in the Bioko Island.
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